ESCAP-2020-CPHG: Treatment Strategies Follow-up Implemented During the First Three Years Following Primary Lung Cancer (PLC) Diagnosed in KBP-2020-CPHG Cohort Patients

Lung Cancer Clinical Trial

— ESCAP-2020  

Official title:

ESCAP-2020-CPHG: Treatment Strategies Follow-up Implemented During the First Three Years Following Primary Lung Cancer (PLC) Diagnosed in KBP-2020-CPHG Cohort Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04419155
• Other study ID #: A00943-54
• Status: Recruiting
• Start date: January 1, 2020
• Est. completion date: December 31, 2023

Study information

• Verified date: June 2020
• Source: Collège des Pneumologues des Hôpitaux Généraux
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The prognosis for primary lung cancer (PLC) is very limited. In France, patients diagnosed for PLC in 2010 and followed in Respiratory Medicine or Oncology department of a General Hospital Centre had a 5-year survival rate of 12.7% (vs 10% in 2000).

Over the last ten years, substantial improvements have been made both in terms of diagnostic (immunohistochemistry and molecular biology) and therapeutic. New treatments have been marketed and are now available in clinic.

New therapeutical strategies have been launched and have proved their efficacy in clinical studies or meta-analyses, generally increasing the survival rate of patients by a few months. However, little information still exists on the use and effectiveness of these molecules in clinical practice.

The CPHG proposes to complete the information collected during KPB-2020-CPHG study by the ESCAP-2020-CPHG study that is a follow-up of therapeutical strategies over the first 3 years of treatment. This study should improve knowledge of the PLC treatment management in General Hospital Centres.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020*

• Follow-up by a lung specialist at a General Hospital

• Oral informed consent * date of collected sample

Exclusion Criteria:

• Age < 18 years

• Secondary lung cancer

• Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery

• Previous enrolment in the study

• Freedom deprived patient following a legal or administrative decision

• Patient unable to give his(her) consent

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Locations

Country	Name	City	State
France	Collège des Pneumologues des Hôpitaux Généraux (CPHG) (General Hospital Pulmonologists College)	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Collège des Pneumologues des Hôpitaux Généraux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Describe therapeutical strategies implemented by pulmonologists in Respiratory Medicine or Oncology department of a General Hospital Centres during the first three years following PLC diagnosed in KBP-2020-CPHG cohort patients.	Data collected for the ESCAP-2020-CPHG study: - All treatments administered	3 years